Magnus Medical

Website

Magnus Medical, Inc.

10 Investors
Neuromodulation Technology
BURLINGAME, CA

Magnus Medical, Inc. is a pioneering medical device company that specializes in developing advanced neuromodulation technology aimed at addressing major depressive disorder (MDD). With a focus on innovative treatments for those suffering from treatment-resistant depression, Magnus Medical is at the forefront of mental health solutions, utilizing cutting-edge neuroscience to improve patient outcomes.

Products & Team

SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy)

Medical DeviceSeed

The SAINT system is an advanced neuromodulation device that employs transcranial magnetic stimulation (TMS) to deliver individualized and accelerated treatment for major depressive disorder. This innovative approach focuses on identifying precise brain targets, ensuring that treatment is tailored to the unique physiology of each patient.

Value Proposition

SAINT effectively resolves the challenges faced by patients with treatment-resistant depression by providing a faster-acting alternative to traditional antidepressants, particularly for those who have experienced inadequate responses to existing medications.

Pain Points

Magnus Medical addresses the significant issue of treatment-resistant depression, offering hope to patients who feel hopeless due to the ineffectiveness of conventional therapies.

Utilizes structural and functional MRI scans for personalized brain target identificationDelivers high-dose intermittent theta burst stimulation (iTBS)Offers a rapid and efficient 5-day treatment protocol
Industry
Biotechnology
Primary business sector
Founded
2025
Year established
Location
BURLINGAME, CA
Primary headquarters

Funding History

Total Raised:
$40.3M
E

Equity Offering

February 2025
$59.0M
Target
Progress
68%
Raised
$40.3M
Target
$59.0M
#000205731225000001